Get the Stockscreener App
92.54
0.40%
0.26
Lemaitre Vascular Inc stock is traded at $92.54, with a volume of 105.29K.
It is up +0.40% in the last 24 hours and up +10.71% over the past month.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
See More
Previous Close:
$92.28
Open:
$91.89
24h Volume:
105.29K
Relative Volume:
0.67
Market Cap:
$2.09B
Revenue:
$213.03M
Net Income/Loss:
$41.32M
P/E Ratio:
50.57
EPS:
1.83
Net Cash Flow:
$33.49M
1W Performance:
+9.82%
1M Performance:
+10.71%
6M Performance:
-4.43%
1Y Performance:
+10.61%
1-Day Range:
$91.38
$93.30
1-Week Range:
$83.61
$97.02
52-Week Range:
$71.42
$109.58
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LMAT
Lemaitre Vascular Inc
|
92.52 | 2.11B | 213.03M | 41.32M | 33.49M | 1.83 |
|
ISRG
Intuitive Surgical Inc
|
470.39 | 168.51B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
191.76 | 49.42B | 21.39B | 1.59B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
283.91 | 41.12B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
84.76 | 41.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
240.84 | 17.06B | 2.90B | 467.20M | 306.90M | 6.37 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
LeMaitre Vascular stock holds Neutral rating at Cantor after strong Q2 - Investing.com Nigeria
LeMaitre Vascular, Inc. to Issue Quarterly Dividend of $0.20 (NASDAQ:LMAT) - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Shares Gap Up After Earnings Beat - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price - MarketBeat
Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 100,000 Shares of Stock - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Announces Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2025 Earnings Guidance - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2025 Earnings Guidance - MarketBeat
LeMaitre Vascular Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Q3 EPS Estimate for LeMaitre Vascular Increased by Analyst - MarketBeat
Q3 Earnings Estimate for LMAT Issued By Barrington Research - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Outperform at Barrington Research - MarketBeat
Lemaitre Vascular Insider Sales: Signal of Caution or Strategic Wealth Management? - AInvest
Q2 EPS Estimate for LeMaitre Vascular Lifted by Analyst - MarketBeat
LeMaitre Vascular To Go Ex-Dividend On August 21st, 2025 With 0.2 USD Dividend Per Share - 富途牛牛
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2025 Earnings Call Transcript - Insider Monkey
LeMaitre Vascular’s Earnings Call Highlights Growth - TipRanks
LeMaitre Vascular Beats Expectations With Strong Sales And Profits - Finimize
Why LeMaitre (LMAT) Stock Is Trading Up Today - TradingView
LeMaitre Vascular Breaks Above 200-Day Moving AverageBullish for LMAT - Nasdaq
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate - simplywall.st
LEMAITRE VASCULAR INC SEC 10-Q Report - TradingView
LeMaitre (LMAT) Q2 Revenue Jumps 15% - sharewise.com
LeMaitre Vascular Reports Impressive Q2 2025 Financial ResultsNews and Statistics - IndexBox
LeMaitre Vascular Q2 Earnings, Revenue Rise; Raises 2025 Guidance - MarketScreener
LeMaitre raises 2025 revenue guidance to $251M with 15% organic growth as international launches accelerate - MSN
LeMaitre: Q2 Earnings Snapshot - New Haven Register
LeMaitre Vascular Inc (LMAT) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
LeMaitre Vascular Inc (LMAT) Q2 2025 Earnings Call Highlights: S - GuruFocus
LeMaitre (LMAT) Q2 Revenue Jumps 15% - The Motley Fool
LeMaitre Vascular's Q2 2025 Earnings Call: Unpacking Key Contradictions in Sales Growth, Pricing Strategies, and Market Opportunities - AInvest
LeMaitre Vascular Reports Strong Q2 2025 Growth - TipRanks
LeMaitre Vascular Ups Guidance After Strong Q2 Sales Jump - Finimize
Earnings call transcript: LeMaitre Vascular Q2 2025 earnings beat forecasts By Investing.com - Investing.com Canada
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
LeMaitre (NASDAQ:LMAT) Exceeds Q2 Expectations, Full-Year Sales Guidance is Optimistic - TradingView
LeMaitre Vascular earnings beat by $0.03, revenue topped estimates - Investing.com South Africa
Medical device firm LeMaitre Q2 sales beat expectations - MarketScreener
LeMaitre Vascular, Inc. Reports Q2 2025 Financial Results, Announces Dividend, and Raises Guidance - Quiver Quantitative
LeMaitre Q2 2025 Financial Results - GlobeNewswire
Why LeMaitre Vascular Inc. stock attracts strong analyst attentionLow Risk Trade Timing with Analysis Metrics - Newser
Detecting support and resistance levels for LeMaitre Vascular Inc.Consistent Profit Signals with AI Models - Newser
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.21%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):